Skip to content

Taysha Gene Therapies, Inc. TSHA Operating Lease Liabilities (Current)

Operating Lease Liabilities (Current) at other companies

Acadia Pharmaceuticals logo
Acadia PharmaceuticalsACAD
$11.79M+3.7%
uniQure logo
uniQureQURE
$2.99M-19.1%
Precigen logo
PrecigenPGEN
$1.07M+15.1%
MapLight Therapeutics, Inc.
 logo
MapLight Therapeutics, Inc. MPLT
$920K
CRISPR Therapeutics logo
CRISPR TherapeuticsCRSP
$18.61M+6.3%
PTC Therapeutics logo
PTC TherapeuticsPTCT
$12.08M+5.4%

Other financials

Income statement

See full
Revenue--100%
Operating income-$43.5M-103%
Net income-$42.4M-97.0%
EPS (diluted)-$0.12-50.0%

Balance sheet

See full
Cash & equivalents$276.6M+137%
Total debt$68.6M+11.2%
Total equity$211.9M+285%
Total assets$300.4M+117%

Cash flow

See full
Operating cash flow-$40.9M-85.6%
CapEx$24.0K-93.7%
Free cash flow-$40.9M-82.6%

Valuation

See full
Market cap$1.99B+351%

Profitability

See full
Operating margin-1,774.4%+1,437pp
Net margin-1,738.4%+1,407pp
FCF margin-1,503.6%+621pp

Returns & leverage

See full
Return on equity-97.3%-27.3pp
Debt / equity0.3×-0.8×
Current ratio14×+8.7×

Where this comes from

Reported directly by Taysha Gene Therapies, Inc. in its filing.

Tagged under the XBRL concept us-gaap:OperatingLeaseLiabilityCurrent.

The official record: Taysha Gene Therapies, Inc.’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →

Ask your AI about Taysha Gene Therapies, Inc.'s operating lease liabilities (current).

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Taysha Gene Therapies, Inc.'s operating lease liabilities (current)?
Taysha Gene Therapies, Inc. (TSHA) reported operating lease liabilities (current) of $1.55M in Q1 2026.
How has Taysha Gene Therapies, Inc.'s operating lease liabilities (current) changed year-over-year?
Taysha Gene Therapies, Inc.'s operating lease liabilities (current) increased by 10.2% year-over-year, from $1.41M to $1.55M.
What is the long-term trend for Taysha Gene Therapies, Inc.'s operating lease liabilities (current)?
Over 3 years (2022 to 2025), Taysha Gene Therapies, Inc.'s operating lease liabilities (current) has grown at a 7.4% compound annual growth rate (CAGR), from $1.2M to $1.49M.
What does operating lease liabilities (current) mean?
The current portion of operating lease obligations due within one year, representing committed future lease payments under ASC 842.